stockrowMirum Pharmaceuticals, Inc.
MIRM Healthcare Biotechnology
Mirum Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $521.3 million, up 54.7% from fiscal 2024.
- Revenue
- +39.6%
- EPS
- −1,136.8%
- Free cash flow
- −114.2%
- Total debt
- +136.4%
Quarter to September 2026, against a year earlier
Follow MIRM
Alert me
Mirum Pharmaceuticals, Inc. (MIRM) Debt to equity
Mirum Pharmaceuticals, Inc.'s debt to equity at the end of the quarter to 30 September 2026 was −13.5×, down 14.5× from fiscal 2025 (1.0×). Over the past ten years it has ranged from 0.0× (fiscal 2018) to 1.4× (fiscal 2024); the current reading is higher than 50% of that period. That is below the Biotechnology industry median of 0.0× and below the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 1.0× | (27.90%) |
| FY2024 | 1.4× | 10.81% |
| FY2023 | 1.2× | 23.59% |
| FY2022 | 1.0× | (9.08%) |
| FY2021 | 1.1× | 275.29% |
| FY2020 | 0.3× | 1,073.49% |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Sep 2026 | −13.5× | — |
| Jun 2026 | −72.0× | — |
| Mar 2026 | 1.3× | 29.95% |
| Dec 2025 | 1.0× | (7.06%) |
| 29 more quarters | Free account |
Against its own ten years
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | −14.9× |
| MIRM Mirum Pharmaceuticals, Inc. | −13.5× |
| BLTE Belite Bio, Inc. Sponsored ADR compare | 0.0× |
| IMVT Immunovant, Inc. compare | 0.0× |
| ORKA Oruka Therapeutics, Inc. compare | 0.0× |
| KOD Kodiak Sciences Inc. compare | 0.0× |
| CGON CG Oncology, Inc. compare | 0.0× |
| LGND Ligand Pharmaceuticals Incorporated compare | 0.7× |
| IONS Ionis Pharmaceuticals, Inc. compare | 3.1× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on MIRM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement